Could & Baker Nigeria Plc printed its full-year 2025 unaudited outcomes, reporting a revenue earlier than tax of N6.55 billion for the 12 months, a big enchancment from the N2.57 billion recorded in 2024.
For the fourth quarter, the corporate posted a revenue earlier than tax of N1.64 billion, in contrast with a loss earlier than tax of N168.46 million in This fall 2024, reflecting a robust year-on-year turnaround.
Throughout each the full-year and fourth-quarter efficiency, robust pharmaceutical gross sales, decrease administrative bills, and curiosity earnings supported the corporate’s bottom-line profitability.
This progress was additionally mirrored within the firm’s earnings per share, which rose to N2.58 from N0.93, indicating an enchancment in shareholder returns.
Income for the 12 months hit N38.2 billion, pushed primarily by the pharmaceutical section, which generated N37.77 billion or 98.72% and accounting for the overwhelming majority of group turnover.
Because of this, working revenue greater than doubled to N6.5 billion, up from N2.5 billion, reflecting wholesome operational effectivity.
Complete fairness additionally swelled to N13.6 billion from N9.8 billion, with retained earnings of N9.3 billion making up the majority of the rise.
On the liabilities aspect, whole obligations declined to N11.9 billion from N12.5 billion, as borrowings narrowed to N3.3 billion from N3.5 billion.
Could & Baker Nigeria Plc’s shares are at the moment priced at N43.45, delivering a month-to-date return of 24.14% in February 2026.
Yr-to-date, the inventory has surged 128.68%, doubtless pushed by constructive sentiment within the pharmaceutical sector and optimism across the firm’s robust {financial} efficiency.
